live sessions
PDT:
Pacific Daylight Time
PDT:
Pacific Daylight Time
Tuesday (March 11) Sessions
Live Now:
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Tuesday
Wafaa M. El-Sadr
ICAP at Columbia University, New York, NY, USA
8:35 AM8:35 AM
27 - HIV Acquisition and Prevention During Pregnancy and Postpartum
John Kinuthia
Kenyatta National Hospital, Nairobi, Kenya
9:05 AM9:05 AM
28 - Systems Vaccinology
Bali Pulendran
Stanford University, Stanford, CA, USA
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
What Do Viruses Do, and How Do They Do It?
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
133 - Replication-Competent HIV-Infected Cells Have Deoxyuracil-Containing Proviruses
Rodrigo Matus Nicodemos
Vaccine Research Center, Bethesda, MD, USA
10:13 AM10:13 AM
134 - Gag-Mediated Control Over CARD8 Activation During HIV-1 Assembly
Ivy K. Hughes
Boston University, Boston, MA, USA
10:21 AM10:21 AM
135 - Direct Visualization of HIV-1 Nuclear Import and Its Interplay With the Nuclear Pore
Yao Shen
University of Oxford, Oxford, UK
10:29 AM10:29 AM
136 - Visualizing the Cell Biology of HIV Latency and Reactivation
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
137 - Single-Cell Spatial Profiling Identified Intact HIV+ Cells in Lymph Nodes
Amare Eshetu
Yale University, New Haven, CT, USA
11:08 AM11:08 AM
138 - Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells
Clayton Faua
University Hospital of Strasbourg, Strasbourg, France
11:16 AM11:16 AM
139 - RhCMV Expands CCR5 Memory CD4 T Cells and Increases Acute-Phase Seeding of SIV DNA in the Gut Mucosa
Chrysostomos Perdios
Tulane National Primate Research Center, Covington, LA, USA
11:24 AM11:24 AM
140 - Differential Replication, Innate Immune Control, and Virulence of Global and Endemic Clade II MPXV
Rebecca P. Sumner
University Surrey, Guildford, UK
11:32 AM11:32 AM
141 - Nef Modulates Actin to Prevent Postintegration Sensing of HIV-1
Alexandre Laliberté
Ulm University Medical Center, Ulm, Germany
11:40 AM11:40 AM
(Questions and Answers Part 2)
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
142 - Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays
Rafael Tiburcio
University of California San Francisco, San Francisco, CA, USA
10:13 AM10:13 AM
143 - Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial, 2022-24
Sufia Dadabhai
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:21 AM10:21 AM
144 - T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV
Devi Sengupta
Gilead Sciences, Inc, Foster City, CA, USA
10:29 AM10:29 AM
145 - Lymph Node HIV-Specific CD8 T Cells of HIV Controllers Harbour a Specific Transcriptomic Signature
Andrea Mastrangelo
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
146 - HIV-Specific CD8+ T Cell Stemness Predicts Postintervention Control of Viremia
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:08 AM11:08 AM
147 - Immunologic Impact of Short-Term BCL2 Inhibition at ART Initiation on SIV-Infected Rhesus Macaques
Tomas Raul Wiche Salinas
Emory University, Atlanta, GA, USA
11:16 AM11:16 AM
148 - Bispecific Antibody VRC07/PGT121 Protects Against High-Dose Intravenous SHIV-BG505 Challenge
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
11:24 AM11:24 AM
149 - Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs
Mauro Garcia
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
11:32 AM11:32 AM
150 - Broad V2-Apex bNAb Activity in HIV-1 Through a Novel, K169-Independent bNAb
Maria C. Hesselman
University of Zurich, Zurich, Switzerland
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
151 - Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome
Onyema Ogbuagu
Yale University, New Haven, CT, USA
10:13 AM10:13 AM
152 - Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor
Luise Rogg
ViiV Healthcare, Durham, NC, USA
10:21 AM10:21 AM
153 - Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor
Paul Benn
ViiV Healthcare, Brentford, UK
10:29 AM10:29 AM
154 - Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir
Renu Singh
Gilead Sciences, Inc, Foster City, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
155 - Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
11:08 AM11:08 AM
156 - Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir
Kerri J. Penrose
University of Pittsburgh, Pittsburgh, PA, USA
11:16 AM11:16 AM
157 - Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
Mackenzie Cottrell
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:24 AM11:24 AM
158 - Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: Phase II Trial
Shey-Ying Chen
National Taiwan University Hospital, Taipei, Taiwan
11:32 AM11:32 AM
159 - Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx
William A. Fischer II
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
New Frontiers in STI Prevention
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
160 - Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening
Kimberly A. Stanford
University of Chicago Medical Center, Chicago, IL, USA
10:13 AM10:13 AM
161 - Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis
Kelly A. Johnson
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
162 - DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC
Amanda D. Castel
The George Washington University, Washington, DC, USA
10:29 AM10:29 AM
163 - High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation
Hyman Scott
San Francisco Department of Public Health, San Francisco, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
164 - The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco
Michael P. Barry
San Francisco AIDS Foundation, San Francisco, CA, USA
11:08 AM11:08 AM
165 - Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV
Namwa Wongkalasin
Imperial College London, London, UK
11:16 AM11:16 AM
166 - Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:24 AM11:24 AM
(Questions and Answers Part 2)
1:30 PM1:30 PM
(Session Overview)
Galit Alter
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
1:35 PM1:35 PM
446 - HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells
Amanda M. Dudek
Stanford University, Stanford, CA, USA
1:40 PM1:40 PM
447 - Differential CD8T/NK Cell-Mediated HIV-1 Control After TIGIT or KLRG1 Blockade and ART in hBLT Mice
Ildefonso Sánchez-Cerrillo
Hospital Universitario de La Princesa, Madrid, Spain
1:45 PM1:45 PM
448 - Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection
Izumi de los Rios Kobara
Stanford University, Stanford, CA, USA
1:50 PM1:50 PM
445 - NF-kappa-B Signaling in Natural Killer Cells Predicts Post-Treatment HIV Control
Ashley F. George
Gladstone Institutes, San Francisco, CA, USA
1:55 PM1:55 PM
444 - RV550: IL-15 Superagonist N-803 With ART in Acute HIV Infection Enhances T and NK Cell Proliferation
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
SARS-CoV-2 Persistence and Evolutions
1:30 PM1:30 PM
(Session Overview)
Alex Sigal
Africa Health Research Institute, Mtubatuba, South Africa
1:35 PM1:35 PM
313 - SARS-CoV-2 Intra-Host Evolution During Acute Infection in People With COVID-19
Alessia Lai
Universita di Milano, Milan, Italy
1:40 PM1:40 PM
311 - Evolving of Immune Evasion During a SARS-CoV-2 Chronic Infection: A Pathway to Variants of Concern
Rui Galao
King's College London, London, UK
1:45 PM1:45 PM
312 - Genetic Mutation Differences Patterns of SARS-CoV-2 in Immunocompromised Patients Versus Controls
Karen Zafilaza
Assistance Publique – Hôpitaux de Paris, Paris, France
1:50 PM1:50 PM
309 - ScRNA-seq of HRSV/SARS-CoV-2 Co-Infection Reveals Unique Cellular Responses and lncRNA Signatures
Claudia Vanetti
University of Milan, Milan, Italy
1:55 PM1:55 PM
314 - Prevalence, Spread, and Mutation of SARS-CoV-2 Variants in COVID-19 Testing in Salvador, Brazil
Anna Carolina Dantas
Federal University of Bahia, Salvador, Brazil
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
TB Infection and Prevention: Testing, Treatment, and Strategies
1:30 PM1:30 PM
(Session Overview)
Salome Charalambous
The Aurum Institute, Johannesburg, South Africa
1:35 PM1:35 PM
964 - Evaluating the Accuracy of Standard F TB-Feron FIA for TB Infection Diagnosis in Vietnam
Han Thi Nguyen
Karolinska Institute, Stockholm, Sweden
1:40 PM1:40 PM
972 - Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial
Pablo C. Alarcon
University of Cincinnati Medical Center, Cincinnati, OH, USA
1:45 PM1:45 PM
969 - The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard
Jinell White
Alberta Health Services, Calgary, Canada
1:50 PM1:50 PM
971 - Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy
Marcia C. Vermeulen
University of Cape Town, Cape Town, South Africa
1:55 PM1:55 PM
970 - Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV
Dickens Onyango
Kisumu County Department of Medical Services, Public Health, and Sanitation, Kisumu, Kenya
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Machine Learning: Gearing Up for the Future
1:30 PM1:30 PM
Scientific Overview of Machine Learning: Gearing Up for the Future
Julia Marcus
Harvard Pilgrim Health Care Institute, Boston, MA, USA
1:40 PM1:40 PM
1307 - Machine Learning to Predict Persons With HIV at Risk of Falling Out of Care
Thomas Martin
University of California San Diego, La Jolla, CA, USA
1:45 PM1:45 PM
1313 - Enhanced Language Models for Predicting and Understanding HIV Care Disengagement
Junzhe Shao
University of California Berkeley, Berkeley, CA, USA
1:55 PM1:55 PM
1308 - An AI-Powered Preventive Intervention for Stigma and Suicidal Ideation in HIV Self-Management
Diego S. Villanueva Guzman
Research Institute of McGill University Health Centre, Montreal, Canada
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Breaking In and Setting Up Home: From HIV Nuclear Entry and Integration to Viral Gene Expression and Establishing the Reservoir
4:00 PM4:00 PM
29 - How HIV Capsid Breaches the Nuclear Envelope Through Karyopherin Mimicry
David Jacques
University of New South Wales, Sydney, Australia
4:18 PM4:18 PM
30 - How HIV Integrates Into the Genome
Alan N Engelman
Dana–Farber Cancer Institute, Boston, MA, USA
4:36 PM4:36 PM
31 - Transcriptional and Epigenetic Regulation of HIV-1 Gene Expression
Melanie Ott
Gladstone Institutes, San Francisco, CA, USA
4:54 PM4:54 PM
32 - The Landscape of Proviral Integration in the HIV-1 Reservoir and Its Relationship to Latency and Reactivation
Mary Kearney
National Cancer Institute at Frederick, Frederick, MD, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
4:00 PM4:00 PM
33 - Beyond Hot Flashes: Women's Lived Experience of Menopause
Bridgette Picou
The Well Project: Women's Research Initiative on HIV/AIDS, Brooklyn, NY, USA
4:10 PM4:10 PM
34 - Clinical Management of Women With HIV in Menopause
Sara Looby
Massachusetts General Hospital, Boston, MA, USA
4:25 PM4:25 PM
35 - Influence of Hormone Changes on Physiology, Virology, and Immunology
Eileen Scully
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
5:00 PM5:00 PM
Discussion with Audience Questions and Answers
MAR11
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Long-Acting Preexposure Prophylaxis for HIV Prevention
4:00 PM4:00 PM
38 - Game Changed: Navigating the Era of Long-Acting Therapies for HIV Prevention
Jonathan Li
Brigham and Women's Hospital, Boston, MA, USA
4:20 PM4:20 PM
39 - Complexities of HIV Diagnosis: What Lies Beneath
Cheryl C. Johnson
World Health Organization, Geneva, Switzerland
4:40 PM4:40 PM
40 - Long-Acting Preexposure Prophylaxis: Why Can’t We Get to Scale?
Cissy Kityo
Joint Clinical Research Centre, Kampala, Uganda
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
5:00 PM5:00 PM
36 - Long-Acting Treatments for Tuberculosis
Eric Nuermberger
The Johns Hopkins University, Baltimore, MD, USA
5:20 PM5:20 PM
37 - Post-Tuberculosis Disease: Opening Pandora's Box
Brian Allwood
Stellenbosch University, Cape Town, South Africa
6:00 PM6:00 PM
Discussion with Audience Questions and Answers
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
Upcoming:
MAR11
8:30 AMto9:30 AMPDT
12:00 PMto5:00 PMPDT
Tuesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Tuesday
Wafaa M. El-Sadr
ICAP at Columbia University, New York, NY, USA
8:35 AM8:35 AM
27 - HIV Acquisition and Prevention During Pregnancy and Postpartum
John Kinuthia
Kenyatta National Hospital, Nairobi, Kenya
9:05 AM9:05 AM
28 - Systems Vaccinology
Bali Pulendran
Stanford University, Stanford, CA, USA
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
What Do Viruses Do, and How Do They Do It?
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
133 - Replication-Competent HIV-Infected Cells Have Deoxyuracil-Containing Proviruses
Rodrigo Matus Nicodemos
Vaccine Research Center, Bethesda, MD, USA
10:13 AM10:13 AM
134 - Gag-Mediated Control Over CARD8 Activation During HIV-1 Assembly
Ivy K. Hughes
Boston University, Boston, MA, USA
10:21 AM10:21 AM
135 - Direct Visualization of HIV-1 Nuclear Import and Its Interplay With the Nuclear Pore
Yao Shen
University of Oxford, Oxford, UK
10:29 AM10:29 AM
136 - Visualizing the Cell Biology of HIV Latency and Reactivation
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
137 - Single-Cell Spatial Profiling Identified Intact HIV+ Cells in Lymph Nodes
Amare Eshetu
Yale University, New Haven, CT, USA
11:08 AM11:08 AM
138 - Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells
Clayton Faua
University Hospital of Strasbourg, Strasbourg, France
11:16 AM11:16 AM
139 - RhCMV Expands CCR5 Memory CD4 T Cells and Increases Acute-Phase Seeding of SIV DNA in the Gut Mucosa
Chrysostomos Perdios
Tulane National Primate Research Center, Covington, LA, USA
11:24 AM11:24 AM
140 - Differential Replication, Innate Immune Control, and Virulence of Global and Endemic Clade II MPXV
Rebecca P. Sumner
University Surrey, Guildford, UK
11:32 AM11:32 AM
141 - Nef Modulates Actin to Prevent Postintegration Sensing of HIV-1
Alexandre Laliberté
Ulm University Medical Center, Ulm, Germany
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Immunology and Vaccines
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
142 - Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays
Rafael Tiburcio
University of California San Francisco, San Francisco, CA, USA
10:13 AM10:13 AM
143 - Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial, 2022-24
Sufia Dadabhai
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:21 AM10:21 AM
144 - T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV
Devi Sengupta
Gilead Sciences, Inc, Foster City, CA, USA
10:29 AM10:29 AM
145 - Lymph Node HIV-Specific CD8 T Cells of HIV Controllers Harbour a Specific Transcriptomic Signature
Andrea Mastrangelo
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
146 - HIV-Specific CD8+ T Cell Stemness Predicts Postintervention Control of Viremia
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:08 AM11:08 AM
147 - Immunologic Impact of Short-Term BCL2 Inhibition at ART Initiation on SIV-Infected Rhesus Macaques
Tomas Raul Wiche Salinas
Emory University, Atlanta, GA, USA
11:16 AM11:16 AM
148 - Bispecific Antibody VRC07/PGT121 Protects Against High-Dose Intravenous SHIV-BG505 Challenge
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
11:24 AM11:24 AM
149 - Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs
Mauro Garcia
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
11:32 AM11:32 AM
150 - Broad V2-Apex bNAb Activity in HIV-1 Through a Novel, K169-Independent bNAb
Maria C. Hesselman
University of Zurich, Zurich, Switzerland
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
151 - Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome
Onyema Ogbuagu
Yale University, New Haven, CT, USA
10:13 AM10:13 AM
152 - Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor
Luise Rogg
ViiV Healthcare, Durham, NC, USA
10:21 AM10:21 AM
153 - Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor
Paul Benn
ViiV Healthcare, Brentford, UK
10:29 AM10:29 AM
154 - Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir
Renu Singh
Gilead Sciences, Inc, Foster City, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
155 - Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
11:08 AM11:08 AM
156 - Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir
Kerri J. Penrose
University of Pittsburgh, Pittsburgh, PA, USA
11:16 AM11:16 AM
157 - Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
Mackenzie Cottrell
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:24 AM11:24 AM
158 - Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: Phase II Trial
Shey-Ying Chen
National Taiwan University Hospital, Taipei, Taiwan
11:32 AM11:32 AM
159 - Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx
William A. Fischer II
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
New Frontiers in STI Prevention
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
160 - Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening
Kimberly A. Stanford
University of Chicago Medical Center, Chicago, IL, USA
10:13 AM10:13 AM
161 - Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis
Kelly A. Johnson
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
162 - DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC
Amanda D. Castel
The George Washington University, Washington, DC, USA
10:29 AM10:29 AM
163 - High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation
Hyman Scott
San Francisco Department of Public Health, San Francisco, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
164 - The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco
Michael P. Barry
San Francisco AIDS Foundation, San Francisco, CA, USA
11:08 AM11:08 AM
165 - Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV
Namwa Wongkalasin
Imperial College London, London, UK
11:16 AM11:16 AM
166 - Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Natural-Born Killers
1:30 PM1:30 PM
(Session Overview)
Galit Alter
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
1:35 PM1:35 PM
446 - HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells
Amanda M. Dudek
Stanford University, Stanford, CA, USA
1:40 PM1:40 PM
447 - Differential CD8T/NK Cell-Mediated HIV-1 Control After TIGIT or KLRG1 Blockade and ART in hBLT Mice
Ildefonso Sánchez-Cerrillo
Hospital Universitario de La Princesa, Madrid, Spain
1:45 PM1:45 PM
448 - Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection
Izumi de los Rios Kobara
Stanford University, Stanford, CA, USA
1:50 PM1:50 PM
445 - NF-kappa-B Signaling in Natural Killer Cells Predicts Post-Treatment HIV Control
Ashley F. George
Gladstone Institutes, San Francisco, CA, USA
1:55 PM1:55 PM
444 - RV550: IL-15 Superagonist N-803 With ART in Acute HIV Infection Enhances T and NK Cell Proliferation
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
SARS-CoV-2 Persistence and Evolutions
1:30 PM1:30 PM
(Session Overview)
Alex Sigal
Africa Health Research Institute, Mtubatuba, South Africa
1:35 PM1:35 PM
313 - SARS-CoV-2 Intra-Host Evolution During Acute Infection in People With COVID-19
Alessia Lai
Universita di Milano, Milan, Italy
1:40 PM1:40 PM
311 - Evolving of Immune Evasion During a SARS-CoV-2 Chronic Infection: A Pathway to Variants of Concern
Rui Galao
King's College London, London, UK
1:45 PM1:45 PM
312 - Genetic Mutation Differences Patterns of SARS-CoV-2 in Immunocompromised Patients Versus Controls
Karen Zafilaza
Assistance Publique – Hôpitaux de Paris, Paris, France
1:50 PM1:50 PM
309 - ScRNA-seq of HRSV/SARS-CoV-2 Co-Infection Reveals Unique Cellular Responses and lncRNA Signatures
Claudia Vanetti
University of Milan, Milan, Italy
1:55 PM1:55 PM
314 - Prevalence, Spread, and Mutation of SARS-CoV-2 Variants in COVID-19 Testing in Salvador, Brazil
Anna Carolina Dantas
Federal University of Bahia, Salvador, Brazil
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
TB Infection and Prevention: Testing, Treatment, and Strategies
1:30 PM1:30 PM
(Session Overview)
Salome Charalambous
The Aurum Institute, Johannesburg, South Africa
1:35 PM1:35 PM
964 - Evaluating the Accuracy of Standard F TB-Feron FIA for TB Infection Diagnosis in Vietnam
Han Thi Nguyen
Karolinska Institute, Stockholm, Sweden
1:40 PM1:40 PM
972 - Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial
Pablo C. Alarcon
University of Cincinnati Medical Center, Cincinnati, OH, USA
1:45 PM1:45 PM
969 - The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard
Jinell White
Alberta Health Services, Calgary, Canada
1:50 PM1:50 PM
971 - Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy
Marcia C. Vermeulen
University of Cape Town, Cape Town, South Africa
1:55 PM1:55 PM
970 - Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV
Dickens Onyango
Kisumu County Department of Medical Services, Public Health, and Sanitation, Kisumu, Kenya
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Machine Learning: Gearing Up for the Future
1:30 PM1:30 PM
Scientific Overview of Machine Learning: Gearing Up for the Future
Julia Marcus
Harvard Pilgrim Health Care Institute, Boston, MA, USA
1:40 PM1:40 PM
1307 - Machine Learning to Predict Persons With HIV at Risk of Falling Out of Care
Thomas Martin
University of California San Diego, La Jolla, CA, USA
1:45 PM1:45 PM
1313 - Enhanced Language Models for Predicting and Understanding HIV Care Disengagement
Junzhe Shao
University of California Berkeley, Berkeley, CA, USA
1:55 PM1:55 PM
1308 - An AI-Powered Preventive Intervention for Stigma and Suicidal Ideation in HIV Self-Management
Diego S. Villanueva Guzman
Research Institute of McGill University Health Centre, Montreal, Canada
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Breaking In and Setting Up Home: From HIV Nuclear Entry and Integration to Viral Gene Expression and Establishing the Reservoir
4:00 PM4:00 PM
29 - How HIV Capsid Breaches the Nuclear Envelope Through Karyopherin Mimicry
David Jacques
University of New South Wales, Sydney, Australia
4:18 PM4:18 PM
30 - How HIV Integrates Into the Genome
Alan N Engelman
Dana–Farber Cancer Institute, Boston, MA, USA
4:36 PM4:36 PM
31 - Transcriptional and Epigenetic Regulation of HIV-1 Gene Expression
Melanie Ott
Gladstone Institutes, San Francisco, CA, USA
4:54 PM4:54 PM
32 - The Landscape of Proviral Integration in the HIV-1 Reservoir and Its Relationship to Latency and Reactivation
Mary Kearney
National Cancer Institute at Frederick, Frederick, MD, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR11
4:00 PMto5:00 PMPDT
12:00 PMto5:00 PMPDT
Hot Topic: Menopause and HIV
4:00 PM4:00 PM
33 - Beyond Hot Flashes: Women's Lived Experience of Menopause
Bridgette Picou
The Well Project: Women's Research Initiative on HIV/AIDS, Brooklyn, NY, USA
4:10 PM4:10 PM
34 - Clinical Management of Women With HIV in Menopause
Sara Looby
Massachusetts General Hospital, Boston, MA, USA
4:25 PM4:25 PM
35 - Influence of Hormone Changes on Physiology, Virology, and Immunology
Eileen Scully
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
5:00 PM5:00 PM
Discussion with Audience Questions and Answers
MAR11
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Long-Acting Preexposure Prophylaxis for HIV Prevention
4:00 PM4:00 PM
38 - Game Changed: Navigating the Era of Long-Acting Therapies for HIV Prevention
Jonathan Li
Brigham and Women's Hospital, Boston, MA, USA
4:20 PM4:20 PM
39 - Complexities of HIV Diagnosis: What Lies Beneath
Cheryl C. Johnson
World Health Organization, Geneva, Switzerland
4:40 PM4:40 PM
40 - Long-Acting Preexposure Prophylaxis: Why Can’t We Get to Scale?
Cissy Kityo
Joint Clinical Research Centre, Kampala, Uganda
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR11
5:00 PMto6:00 PMPDT
12:00 PMto5:00 PMPDT
Tuberculosis: The Long Game
5:00 PM5:00 PM
36 - Long-Acting Treatments for Tuberculosis
Eric Nuermberger
The Johns Hopkins University, Baltimore, MD, USA
5:20 PM5:20 PM
37 - Post-Tuberculosis Disease: Opening Pandora's Box
Brian Allwood
Stellenbosch University, Cape Town, South Africa
6:00 PM6:00 PM
Discussion with Audience Questions and Answers
MAR11
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 5
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
Previous:
MAR11
8:30 AMto9:30 AMPDT
12:00 PMto5:00 PMPDT
Tuesday Plenary Session
8:30 AM8:30 AM
CROI Program Committee Chair Welcome to Tuesday
Wafaa M. El-Sadr
ICAP at Columbia University, New York, NY, USA
8:35 AM8:35 AM
27 - HIV Acquisition and Prevention During Pregnancy and Postpartum
John Kinuthia
Kenyatta National Hospital, Nairobi, Kenya
9:05 AM9:05 AM
28 - Systems Vaccinology
Bali Pulendran
Stanford University, Stanford, CA, USA
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
What Do Viruses Do, and How Do They Do It?
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
133 - Replication-Competent HIV-Infected Cells Have Deoxyuracil-Containing Proviruses
Rodrigo Matus Nicodemos
Vaccine Research Center, Bethesda, MD, USA
10:13 AM10:13 AM
134 - Gag-Mediated Control Over CARD8 Activation During HIV-1 Assembly
Ivy K. Hughes
Boston University, Boston, MA, USA
10:21 AM10:21 AM
135 - Direct Visualization of HIV-1 Nuclear Import and Its Interplay With the Nuclear Pore
Yao Shen
University of Oxford, Oxford, UK
10:29 AM10:29 AM
136 - Visualizing the Cell Biology of HIV Latency and Reactivation
Jonathan Karn
Case Western Reserve University, Cleveland, OH, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
137 - Single-Cell Spatial Profiling Identified Intact HIV+ Cells in Lymph Nodes
Amare Eshetu
Yale University, New Haven, CT, USA
11:08 AM11:08 AM
138 - Lenacapavir Directs Specific Proteasome-Mediated Degradation of Gag Proteins in HIV-Infected Cells
Clayton Faua
University Hospital of Strasbourg, Strasbourg, France
11:16 AM11:16 AM
139 - RhCMV Expands CCR5 Memory CD4 T Cells and Increases Acute-Phase Seeding of SIV DNA in the Gut Mucosa
Chrysostomos Perdios
Tulane National Primate Research Center, Covington, LA, USA
11:24 AM11:24 AM
140 - Differential Replication, Innate Immune Control, and Virulence of Global and Endemic Clade II MPXV
Rebecca P. Sumner
University Surrey, Guildford, UK
11:32 AM11:32 AM
141 - Nef Modulates Actin to Prevent Postintegration Sensing of HIV-1
Alexandre Laliberté
Ulm University Medical Center, Ulm, Germany
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Immunology and Vaccines
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
142 - Profiling Therapeutic Vaccine-Driven HIV-Specific CD8 T Cells With Single-Cell TCR Sequencing Assays
Rafael Tiburcio
University of California San Francisco, San Francisco, CA, USA
10:13 AM10:13 AM
143 - Efficacy of Bivalent Versus Monovalent COVID-19 Vaccines Among People With HIV, Ubuntu Trial, 2022-24
Sufia Dadabhai
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
10:21 AM10:21 AM
144 - T-Cell Responses Induced by GS-1966+GS-1144 Vaccines in Virally Suppressed People With HIV
Devi Sengupta
Gilead Sciences, Inc, Foster City, CA, USA
10:29 AM10:29 AM
145 - Lymph Node HIV-Specific CD8 T Cells of HIV Controllers Harbour a Specific Transcriptomic Signature
Andrea Mastrangelo
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
146 - HIV-Specific CD8+ T Cell Stemness Predicts Postintervention Control of Viremia
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
11:08 AM11:08 AM
147 - Immunologic Impact of Short-Term BCL2 Inhibition at ART Initiation on SIV-Infected Rhesus Macaques
Tomas Raul Wiche Salinas
Emory University, Atlanta, GA, USA
11:16 AM11:16 AM
148 - Bispecific Antibody VRC07/PGT121 Protects Against High-Dose Intravenous SHIV-BG505 Challenge
Matthew S. Parsons
Armed Forces Research Institute of Medical Sciences in Bangkok, Bangkok, Thailand
11:24 AM11:24 AM
149 - Time-to-Rebound Measurements in ATI Trials With bNAb Intervention Are Confounded by Autologous NAbs
Mauro Garcia
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
11:32 AM11:32 AM
150 - Broad V2-Apex bNAb Activity in HIV-1 Through a Novel, K169-Independent bNAb
Maria C. Hesselman
University of Zurich, Zurich, Switzerland
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
Antivirals For HIV, MPXV, and SARS-CoV-2: New Drug Strategies and Resistance
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
151 - Efficacy and Safety of Lenacapavir, Teropavimab, and Zinlirvimab: Phase II Week 26 Primary Outcome
Onyema Ogbuagu
Yale University, New Haven, CT, USA
10:13 AM10:13 AM
152 - Proof-of-Concept Trial of VH4524184 (VH-184), a Third-Generation Integrase Strand Transfer Inhibitor
Luise Rogg
ViiV Healthcare, Durham, NC, USA
10:21 AM10:21 AM
153 - Proof-of-Concept Trial of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor
Paul Benn
ViiV Healthcare, Brentford, UK
10:29 AM10:29 AM
154 - Pharmacokinetics and Safety of Once-Yearly Formulations of Lenacapavir
Renu Singh
Gilead Sciences, Inc, Foster City, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
155 - Elucidating the Mechanism by Which Nucleocapsid Mutations Confer Resistance to InSTIs
Yuta Hikichi
National Cancer Institute at Frederick, Frederick, MD, USA
11:08 AM11:08 AM
156 - Selection of Nucleocapsid Mutations With Virologic Failure of Tenofovir/Lamivudine/Dolutegravir
Kerri J. Penrose
University of Pittsburgh, Pittsburgh, PA, USA
11:16 AM11:16 AM
157 - Optimizing On-Demand Tenofovir Disoproxil Fumarate/Emtricitabine Dosing in Women for HIV Prevention
Mackenzie Cottrell
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:24 AM11:24 AM
158 - Safety and Antiviral Efficacy of a Broad-Spectrum siRNA SNS812 Targeting SARS-CoV-2: Phase II Trial
Shey-Ying Chen
National Taiwan University Hospital, Taipei, Taiwan
11:32 AM11:32 AM
159 - Host and Disease Factors Were Not Associated With Mpox Resolution in Participants Receiving Tpoxx
William A. Fischer II
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
11:40 AM11:40 AM
(Questions and Answers Part 2)
MAR11
10:00 AMto12:00 PMPDT
12:00 PMto5:00 PMPDT
New Frontiers in STI Prevention
10:00 AM10:00 AM
(Introduction of Speakers Part 1)
10:05 AM10:05 AM
160 - Missed Opportunities for Syphilis Diagnosis With Targeted Compared to Universal Screening
Kimberly A. Stanford
University of Chicago Medical Center, Chicago, IL, USA
10:13 AM10:13 AM
161 - Higher Odds of Congenital Syphilis With 9- vs 7-Day Prenatal Treatment Intervals for Late Syphilis
Kelly A. Johnson
University of California San Francisco, San Francisco, CA, USA
10:21 AM10:21 AM
162 - DoxyPEP Eligibility, Use, and Potential for STI Reduction in a Large HIV Cohort in Washington, DC
Amanda D. Castel
The George Washington University, Washington, DC, USA
10:29 AM10:29 AM
163 - High Sustained Effectiveness of Doxycycline PEP for STI Prevention After Clinical Implementation
Hyman Scott
San Francisco Department of Public Health, San Francisco, CA, USA
10:37 AM10:37 AM
(Questions and Answers Part 1)
10:55 AM10:55 AM
(Introduction of Speakers Part 2)
11:00 AM11:00 AM
164 - The Doxy-PEP Continuum Among Patients Receiving Care at a Sexual Health Clinic in San Francisco
Michael P. Barry
San Francisco AIDS Foundation, San Francisco, CA, USA
11:08 AM11:08 AM
165 - Global Modelling Analysis: Impact of Improved HPV Vaccination on Noncervical Cancers in PLWHIV
Namwa Wongkalasin
Imperial College London, London, UK
11:16 AM11:16 AM
166 - Impact of Urine TFV Testing on PrEP Adherence in South African Pregnant and Postpartum Women: An RCT
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
11:24 AM11:24 AM
(Questions and Answers Part 2)
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Natural-Born Killers
1:30 PM1:30 PM
(Session Overview)
Galit Alter
Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA
1:35 PM1:35 PM
446 - HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells
Amanda M. Dudek
Stanford University, Stanford, CA, USA
1:40 PM1:40 PM
447 - Differential CD8T/NK Cell-Mediated HIV-1 Control After TIGIT or KLRG1 Blockade and ART in hBLT Mice
Ildefonso Sánchez-Cerrillo
Hospital Universitario de La Princesa, Madrid, Spain
1:45 PM1:45 PM
448 - Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection
Izumi de los Rios Kobara
Stanford University, Stanford, CA, USA
1:50 PM1:50 PM
445 - NF-kappa-B Signaling in Natural Killer Cells Predicts Post-Treatment HIV Control
Ashley F. George
Gladstone Institutes, San Francisco, CA, USA
1:55 PM1:55 PM
444 - RV550: IL-15 Superagonist N-803 With ART in Acute HIV Infection Enhances T and NK Cell Proliferation
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
SARS-CoV-2 Persistence and Evolutions
1:30 PM1:30 PM
(Session Overview)
Alex Sigal
Africa Health Research Institute, Mtubatuba, South Africa
1:35 PM1:35 PM
313 - SARS-CoV-2 Intra-Host Evolution During Acute Infection in People With COVID-19
Alessia Lai
Universita di Milano, Milan, Italy
1:40 PM1:40 PM
311 - Evolving of Immune Evasion During a SARS-CoV-2 Chronic Infection: A Pathway to Variants of Concern
Rui Galao
King's College London, London, UK
1:45 PM1:45 PM
312 - Genetic Mutation Differences Patterns of SARS-CoV-2 in Immunocompromised Patients Versus Controls
Karen Zafilaza
Assistance Publique – Hôpitaux de Paris, Paris, France
1:50 PM1:50 PM
309 - ScRNA-seq of HRSV/SARS-CoV-2 Co-Infection Reveals Unique Cellular Responses and lncRNA Signatures
Claudia Vanetti
University of Milan, Milan, Italy
1:55 PM1:55 PM
314 - Prevalence, Spread, and Mutation of SARS-CoV-2 Variants in COVID-19 Testing in Salvador, Brazil
Anna Carolina Dantas
Federal University of Bahia, Salvador, Brazil
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
TB Infection and Prevention: Testing, Treatment, and Strategies
1:30 PM1:30 PM
(Session Overview)
Salome Charalambous
The Aurum Institute, Johannesburg, South Africa
1:35 PM1:35 PM
964 - Evaluating the Accuracy of Standard F TB-Feron FIA for TB Infection Diagnosis in Vietnam
Han Thi Nguyen
Karolinska Institute, Stockholm, Sweden
1:40 PM1:40 PM
972 - Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial
Pablo C. Alarcon
University of Cincinnati Medical Center, Cincinnati, OH, USA
1:45 PM1:45 PM
969 - The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard
Jinell White
Alberta Health Services, Calgary, Canada
1:50 PM1:50 PM
971 - Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy
Marcia C. Vermeulen
University of Cape Town, Cape Town, South Africa
1:55 PM1:55 PM
970 - Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV
Dickens Onyango
Kisumu County Department of Medical Services, Public Health, and Sanitation, Kisumu, Kenya
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
1:30 PMto2:30 PMPDT
12:00 PMto5:00 PMPDT
Machine Learning: Gearing Up for the Future
1:30 PM1:30 PM
Scientific Overview of Machine Learning: Gearing Up for the Future
Julia Marcus
Harvard Pilgrim Health Care Institute, Boston, MA, USA
1:40 PM1:40 PM
1307 - Machine Learning to Predict Persons With HIV at Risk of Falling Out of Care
Thomas Martin
University of California San Diego, La Jolla, CA, USA
1:45 PM1:45 PM
1313 - Enhanced Language Models for Predicting and Understanding HIV Care Disengagement
Junzhe Shao
University of California Berkeley, Berkeley, CA, USA
1:55 PM1:55 PM
1308 - An AI-Powered Preventive Intervention for Stigma and Suicidal Ideation in HIV Self-Management
Diego S. Villanueva Guzman
Research Institute of McGill University Health Centre, Montreal, Canada
2:00 PM2:00 PM
Discussion with Audience Q&A
MAR11
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Breaking In and Setting Up Home: From HIV Nuclear Entry and Integration to Viral Gene Expression and Establishing the Reservoir
4:00 PM4:00 PM
29 - How HIV Capsid Breaches the Nuclear Envelope Through Karyopherin Mimicry
David Jacques
University of New South Wales, Sydney, Australia
4:18 PM4:18 PM
30 - How HIV Integrates Into the Genome
Alan N Engelman
Dana–Farber Cancer Institute, Boston, MA, USA
4:36 PM4:36 PM
31 - Transcriptional and Epigenetic Regulation of HIV-1 Gene Expression
Melanie Ott
Gladstone Institutes, San Francisco, CA, USA
4:54 PM4:54 PM
32 - The Landscape of Proviral Integration in the HIV-1 Reservoir and Its Relationship to Latency and Reactivation
Mary Kearney
National Cancer Institute at Frederick, Frederick, MD, USA
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR11
4:00 PMto5:00 PMPDT
12:00 PMto5:00 PMPDT
Hot Topic: Menopause and HIV
4:00 PM4:00 PM
33 - Beyond Hot Flashes: Women's Lived Experience of Menopause
Bridgette Picou
The Well Project: Women's Research Initiative on HIV/AIDS, Brooklyn, NY, USA
4:10 PM4:10 PM
34 - Clinical Management of Women With HIV in Menopause
Sara Looby
Massachusetts General Hospital, Boston, MA, USA
4:25 PM4:25 PM
35 - Influence of Hormone Changes on Physiology, Virology, and Immunology
Eileen Scully
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
5:00 PM5:00 PM
Discussion with Audience Questions and Answers
MAR11
4:00 PMto5:30 PMPDT
12:00 PMto5:00 PMPDT
Long-Acting Preexposure Prophylaxis for HIV Prevention
4:00 PM4:00 PM
38 - Game Changed: Navigating the Era of Long-Acting Therapies for HIV Prevention
Jonathan Li
Brigham and Women's Hospital, Boston, MA, USA
4:20 PM4:20 PM
39 - Complexities of HIV Diagnosis: What Lies Beneath
Cheryl C. Johnson
World Health Organization, Geneva, Switzerland
4:40 PM4:40 PM
40 - Long-Acting Preexposure Prophylaxis: Why Can’t We Get to Scale?
Cissy Kityo
Joint Clinical Research Centre, Kampala, Uganda
5:30 PM5:30 PM
Discussion with Audience Questions and Answers
MAR11
5:00 PMto6:00 PMPDT
12:00 PMto5:00 PMPDT
Tuberculosis: The Long Game
5:00 PM5:00 PM
36 - Long-Acting Treatments for Tuberculosis
Eric Nuermberger
The Johns Hopkins University, Baltimore, MD, USA
5:20 PM5:20 PM
37 - Post-Tuberculosis Disease: Opening Pandora's Box
Brian Allwood
Stellenbosch University, Cape Town, South Africa
6:00 PM6:00 PM
Discussion with Audience Questions and Answers
MAR11
10:30 PMto10:45 PMPDT
12:00 PMto5:00 PMPDT
Test Session 5
10:30 PM10:30 PM
Test Presentation 1
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
10:30 PM10:30 PM
Test Presentation 2
TestFirstName 1 TestMiddleName 1 TestLastName 1
Institution 1
